Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Indivior Pharmaceuticals Inc. (INDV) vs Kiniksa Pharmaceuticals International, plc (KNSA)

Indivior Pharmaceuticals Inc. and Kiniksa Pharmaceuticals International, plc are both Drug Manufacturers Specialty & Generic companies. Kiniksa Pharmaceuticals International, plc is the larger, with a market value of $5.9B against $4.3B — 1.4× the size. Indivior Pharmaceuticals Inc. trades at the lower P/E: 12.4× against 70.2×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.9% against 13.5%. Indivior Pharmaceuticals Inc. has the higher net margin (26.8% vs 9.59%) and the higher return on invested capital (460.5% vs 48.9%). Across the 18 metrics below, Indivior Pharmaceuticals Inc. leads on 11 and Kiniksa Pharmaceuticals International, plc on 7.

Valuation

Metric INDV KNSA Drug Manufacturers Specialty & Generic median
P/E 12.40 70.17 20.14
P/S 3.20 6.93 2.25
P/B n/m 8.90 1.90
Price to free cash flow n/m 31.84 16.54
EV/EBITDA 10.43 51.93 12.29
EV/Sales 3.42 6.30 2.56
Earnings yield 8.07% 1.43% (2.99%)
Free cash flow yield (2.65%) 3.14% 0.00%

Profitability

Metric INDV KNSA Drug Manufacturers Specialty & Generic median
Gross margin 81.97% 89.82% 53.94%
Operating margin 31.56% 11.92% 0.00%
Net margin 26.75% 9.59% 0.00%
Free cash flow margin (8.34%) 21.74% 0.00%
Return on equity (153.12%) 14.04% (0.40%)
Return on assets 26.52% 10.36% (3.32%)
Return on invested capital 460.53% 48.87% 0.00%

Growth

Metric INDV KNSA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 13.47% 58.85% 10.01%
EPS growth (last fiscal year) 3,017.87% 225.00% —
Revenue growth, 5-year CAGR 13.88% — 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INDV KNSA Drug Manufacturers Specialty & Generic median
Debt to equity (2.34) 0.00 0.05
Current ratio 0.84 3.90 2.31
Net debt to EBITDA 0.44 (5.26) 0.85

Dividend

Metric INDV KNSA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio — 0.00 0.00

Size

Metric INDV KNSA Drug Manufacturers Specialty & Generic median
Market cap 4.25b 5.90b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack